Navigation Links
GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting
Date:8/27/2010

icipants.  She also indicated the screening of the Therapeutic Trial volunteers is on target to begin generating vaccine safety and performance data during 2011, with trial completion within 24 to 36 months.  Mark Reynolds, chief financial officer, provided a financial update and discussed the Company's sources of capital.

HIV/AIDS BackgroundHIV affects the entire globe and comes in a variety of subtypes. Clade B is the predominant subtype in North America where there are roughly 60,000 new infections each year. Globally, there are about 2.5 million AIDS infections per year, most primarily involving subtypes AG, B, and C. In 2007, UNAIDS reported 1.3 million people living with AIDS in North America and 33.2 million people living with AIDS worldwide. Presently, there is little to prevent HIV transmission other than education, circumcision, and condoms. It is obvious from the spread of the disease that these methods are not adequate. Existing treatments for individuals infected with HIV include anti-retroviral therapies that are effective but have serious medical side effects and are very expensive (upwards of $1,500/month). This cost is borne primarily by the individual and sometimes by third party insurance, local healthcare, federal or world health organizations. Development and distribution of an effective HIV/AIDS vaccine holds great promise. The GeoVax vaccine would cost a fraction of the cost of current treatments and, to date, has not elicited serious adverse side effects in several human trials. A population vaccinated with an effective HIV-1 vaccine would be expected to significantly decrease the prevalence of AIDS over time.

About GeoVax Labs, Inc.GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, oversee manufacturing and testing of
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
6. GeoVax to Present at the BIO CEO & Investor Conference 2009
7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
10. GeoVax Labs, Inc. Announces First Quarter Financial Results
11. GeoVax to Exhibit at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014  Spherix Incorporated (Nasdaq: SPEX) -- an intellectual property ... of intellectual property, announced today that the Markman ... in the U.S. District Court for the Northern ... been rescheduled for November 10, 2014.  This hearing ... Court Order setting the Markman date was received ...
(Date:10/1/2014)... Jolla, Calif. (PRWEB) September 30, 2014 ... announced the initial round of grants for the ... an undertaking that aims to develop and revolutionize ... circuit functions of the human brain. This first ... for fiscal year 2014 was allocated to more ...
(Date:10/1/2014)... Centreville, VA (PRWEB) October 01, 2014 ... the Diagnostic, Clinical Therapeutics, Healthcare IT, and Laboratory Testing ... and regulatory positions at the director level and above ... payers struggling to stay on top of rapid breakthroughs ... a result, many diagnostic companies have been forced to ...
(Date:10/1/2014)... Industry leaders from retail pharmacies to ... theme, ,Commercial Opportunities in the Era of Reform, from ... Elsevier , a world-leading provider of scientific, technical and ... of some of the industry,s most prominent healthcare leaders ... in the future. The Elsevier Healthcare and ...
Breaking Biology Technology:Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... on Custom Medical Devices, SOUTH ORANGE, N.J., Aug. ... -- Vincent J. Capricci, 56, is a former public,school ... avid,hunter, golfer and fisherman. After minor surgery a few ... his ankle joint.,He was out of work for nine ...
... has appointed FBI Supervising Special Agent (Ret.) Dr. Philip Hayden as its ... ... (Business Wire EON) August 18, 2008 -- Dr. Hayden comes to ... Dr. Philip Hayden has spent years involved in many aspects of law ...
... Includes $10 Million in Upfront Fees and Milestones ... INC.,(OTC Bulletin Board: ACCP) and Milestone Biosciences, LLC ... agreement under which,Milestone will market Access, proprietary product ... a company recently started by former,executives and sales ...
Cached Biology Technology:FDA Gets Knocked Out in Endotec, Inc. Ruling 2FDA Gets Knocked Out in Endotec, Inc. Ruling 3 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 2 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 3 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 4Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America 2Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America 3
(Date:10/2/2014)... 2014 The global genomics market was valued ... grow at a CAGR of over 12.0% from 2013 ... expansion of genomics applications, and advancements in existing technologies ... to invest in this market. Next Generation Sequencing (NGS) ... a high growth area for the global genomics market. ...
(Date:10/1/2014)... hope to take a healthy salad up a level ... breast cancer in leafy greens. , "In the long ... by eating the salad or making a pill from ... biomedical engineering at Case Western Reserve School of Medicine ... Komen breast cancer organization is funding the research with ...
(Date:10/1/2014)... , October 1, 2014 ... in the life science field  The ... come and go over the years. Some are ... Photon upconversion is a novel detection technology that ... years. Now, finally, this technology is becoming commercially ...
Breaking Biology News(10 mins):Genomics Market by Products - [Instruments (NGS platform, Microarray, RT-PCR), Consumables (Genechips, Reagents for DNA Extraction & Purification, Sequencing)], Services (Sequencing & Microarray Services, and Software) - Global Forecast to 2018 2Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3First-of-a-kind Solution for Utilizing Photon Upconversion 2
... noses and Microsoft Windows, infamous blue screen of death ... being made by a new research report appearing online ... Specifically, scientists now know exactly why we sneeze, what ... not work properly. Much like a temperamental computer, our ...
... Olympic athletes may be the best trained and physically ... susceptible to back pain. BackPainRelief.net is releasing an infographic ... injuries can be avoided. (Photo: ... for a number of injuries, and back pain is ...
... (July 30, 2012) When the longest cells in the body ... is no easy task. This is in part because these ... one meter in adult humans which is a lot ... order to reach the "command center" of the cell,s nucleus. ...
Cached Biology News:Allergies? Your sneeze is a biological response to the nose's 'blue screen of death' 2Backpainrelief.net Tackles Sports Injuries with Infographic 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 3
... of Class II Biological Safety Cabinets ... to the world's highest safety standards. ... cabinets cannot be adjusted out of ... noise and arm rest ensure safety ...
... The Holten MaxiSafe 2010 Class II ... ergonomical working condition of comfort while ... efficiency and performance.,Refined operator, environment and ... both exhausted and recirculated air.,Bottom filters ...
... is designed for paramagnetic bead precipitation from ... PCR plates with no additional accessories. The ... a standard SBS 96-well microplate footprint. The ... guarantees easy and fast (as little as ...
... Minidizer is a personal desktop unit ideal for ... requirements. , Rotation speed set at 12 ... 80o C , Bottle capacity of four ... 15 ml conical ,plastic bottles , Consistent, ...
Biology Products: